drug discovery

Researchers use label-free surface plasmon resonance to measure affinity and binding kinetics in real time. 

Hundreds of bispecific antibodies are in development for imaging, diagnostic, and therapeutic applications against diseases such as cancer. 

In this webinar, Tim Heiseler will discuss the importance of assay design when measuring binding kinetics and affinity values, as well as strategies to mitigate avidity effects.

Using the Incucyte® AI Cell Health Analysis Software Module, researchers quantify cell viability from microscopy images without needing fluorescent labels.

Vaccination against one SARS-CoV-2 variant can yield antibodies with efficacy against other viral variants.

Advanced flow cytometers reduce the need for scientists to use multiple devices to analyze cell-based assays. 

Surface plasmon resonance and Bio-layer interferometry offer advantages when investigating biological mechanisms and developing new therapeutics.

Through a combination of basic science research and clinical trials, researchers uncover innovative approaches for targeted cancer treatment. 

An overview of the Transcreener ADPR assay

Discover the top five reasons researchers need modern medical imaging infrastructure.

Translational research and drug discovery meet at the intersection of novel multiomics technologies.

Electron activated dissociation (EAD) and the Zeno trap provide high sensitivity and certainty in mass spectrometry results.

An expanded, high-quality chemical library provides efficient hit series identification of drug candidates.

Scientists combine microplate readers and cell-based assays for high throughput and reduced variability across a variety of applications.

A guide to biochemical assays for measuring drug-target interactions

Electron activated dissociation (EAD) and the Zeno trap provide high sensitivity and certainty in mass spectrometry results. 

Discover tips for setting up and optimizing adeno-associated virus production.

Automation, high-throughput capabilities, and improved technologies and reagents accelerate cell profiling and screening.

Overcome drug resistance by targeting host proteins.

Scientists engineered a lung-on-a-chip model from patient cells that mimics cystic fibrosis.